Compare HIPO & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIPO | WVE |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 907.5M | 744.8M |
| IPO Year | 2020 | 2015 |
| Metric | HIPO | WVE |
|---|---|---|
| Price | $36.90 | $3.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 21 |
| Target Price | ★ $40.88 | $17.22 |
| AVG Volume (30 Days) | 161.2K | ★ 2.9M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 235.37 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $468,600,000.00 | $3,704,000.00 |
| Revenue This Year | $24.25 | $19.15 |
| Revenue Next Year | $34.47 | N/A |
| P/E Ratio | $54.66 | ★ N/A |
| Revenue Growth | 25.93 | ★ 149.43 |
| 52 Week Low | $24.08 | $3.04 |
| 52 Week High | $38.73 | $21.73 |
| Indicator | HIPO | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 72.52 | 26.33 |
| Support Level | $24.68 | N/A |
| Resistance Level | N/A | $4.07 |
| Average True Range (ATR) | 0.88 | 0.17 |
| MACD | 0.37 | -0.00 |
| Stochastic Oscillator | 93.51 | 12.14 |
Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.